Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
Titel:
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
Auteur:
Macaulay, V.M. Middleton, M.R. Protheroe, A.S. Tolcher, A. Dieras, V. Sessa, C. Bahleda, R. Blay, J.-Y. LoRusso, P. Mery-Mignard, D. Soria, J.-C.